| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Appendiceal Neoplasms | 6 | 2024 | 254 | 0.990 |
Why?
|
| Colitis | 4 | 2022 | 340 | 0.620 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 68 | 0.530 |
Why?
|
| Simplexvirus | 1 | 2016 | 181 | 0.510 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 98 | 0.490 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2023 | 1831 | 0.420 |
Why?
|
| Nasopharyngeal Neoplasms | 14 | 2003 | 340 | 0.420 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 1754 | 0.360 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 3707 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2016 | 1246 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5258 | 0.320 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 7920 | 0.290 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 1010 | 0.290 |
Why?
|
| Biopsy | 6 | 2020 | 3490 | 0.250 |
Why?
|
| Observer Variation | 2 | 2024 | 709 | 0.240 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 503 | 0.240 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 506 | 0.230 |
Why?
|
| Immunohistochemistry | 6 | 2024 | 7648 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 5246 | 0.220 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 414 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 3155 | 0.210 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 866 | 0.210 |
Why?
|
| Pancreatitis, Chronic | 1 | 2023 | 127 | 0.210 |
Why?
|
| DNA Mismatch Repair | 2 | 2023 | 289 | 0.200 |
Why?
|
| Middle Aged | 38 | 2024 | 90533 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2022 | 1032 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2017 | 5604 | 0.190 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2020 | 19 | 0.170 |
Why?
|
| Diarrhea | 2 | 2021 | 722 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 445 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2024 | 765 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2021 | 184 | 0.160 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 108 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 180 | 0.160 |
Why?
|
| Neoplasms | 6 | 2024 | 15949 | 0.160 |
Why?
|
| Aged | 31 | 2024 | 73613 | 0.160 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 10726 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 514 | 0.160 |
Why?
|
| Genomics | 3 | 2021 | 2832 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 289 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5417 | 0.160 |
Why?
|
| Male | 38 | 2024 | 128479 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 561 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 107 | 0.140 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 31116 | 0.140 |
Why?
|
| Humans | 49 | 2024 | 270713 | 0.140 |
Why?
|
| Patient Comfort | 1 | 2016 | 7 | 0.140 |
Why?
|
| Foscarnet | 1 | 2016 | 19 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 1656 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2018 | 703 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2021 | 1420 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2016 | 485 | 0.140 |
Why?
|
| Acyclovir | 1 | 2016 | 79 | 0.130 |
Why?
|
| Stem Cell Factor | 1 | 2016 | 83 | 0.130 |
Why?
|
| Transaminases | 1 | 2016 | 77 | 0.130 |
Why?
|
| Smad2 Protein | 1 | 2016 | 89 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 69 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 4468 | 0.130 |
Why?
|
| Valine | 1 | 2016 | 179 | 0.130 |
Why?
|
| Female | 37 | 2024 | 148885 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2016 | 114 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1388 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2020 | 946 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1095 | 0.120 |
Why?
|
| Adult | 28 | 2024 | 82041 | 0.120 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2015 | 41 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 291 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 616 | 0.120 |
Why?
|
| Liver | 4 | 2017 | 3057 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2017 | 10404 | 0.120 |
Why?
|
| Prognosis | 11 | 2023 | 22528 | 0.120 |
Why?
|
| Microsatellite Instability | 3 | 2023 | 413 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2016 | 818 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2019 | 558 | 0.110 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2014 | 39 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 107 | 0.110 |
Why?
|
| Calcinosis | 1 | 2017 | 427 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2012 | 757 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 481 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 2658 | 0.110 |
Why?
|
| Cholestasis | 1 | 2016 | 208 | 0.110 |
Why?
|
| Retrospective Studies | 23 | 2024 | 39959 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 1337 | 0.110 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 4839 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 517 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 562 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 1270 | 0.100 |
Why?
|
| Neoplasm Staging | 11 | 2018 | 14033 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 16741 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 522 | 0.100 |
Why?
|
| Lymphangioma, Cystic | 1 | 2012 | 23 | 0.100 |
Why?
|
| Survival Rate | 9 | 2023 | 12530 | 0.100 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2012 | 110 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2014 | 610 | 0.090 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 227 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 3464 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2012 | 251 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 3048 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1854 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2017 | 2124 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3427 | 0.080 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2023 | 521 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 999 | 0.080 |
Why?
|
| Young Adult | 6 | 2021 | 22243 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2012 | 511 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1956 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2014 | 1626 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 7787 | 0.070 |
Why?
|
| Neoplasm Metastasis | 4 | 2024 | 5332 | 0.070 |
Why?
|
| Lymphoma | 1 | 2016 | 1516 | 0.070 |
Why?
|
| Colonoscopy | 2 | 2021 | 524 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 3241 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2023 | 690 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4966 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5145 | 0.060 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 2811 | 0.060 |
Why?
|
| Mutation | 4 | 2020 | 15917 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4394 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1828 | 0.060 |
Why?
|
| Risk Factors | 5 | 2021 | 17861 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 1435 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2024 | 232 | 0.050 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 155 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2023 | 114 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 2191 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1995 | 303 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6257 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 229 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 16244 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3054 | 0.050 |
Why?
|
| Leucovorin | 1 | 2023 | 345 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 2258 | 0.050 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2021 | 33 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2363 | 0.050 |
Why?
|
| Age Distribution | 2 | 2019 | 727 | 0.050 |
Why?
|
| Mucins | 1 | 2023 | 289 | 0.050 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 78 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 455 | 0.050 |
Why?
|
| Adolescent | 14 | 2019 | 32689 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 85 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 164 | 0.050 |
Why?
|
| Treatment Outcome | 8 | 2021 | 33847 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 274 | 0.050 |
Why?
|
| Time Factors | 6 | 2020 | 12978 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 46 | 0.040 |
Why?
|
| Chromogranins | 1 | 2020 | 87 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 3656 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2021 | 149 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 225 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2023 | 13419 | 0.040 |
Why?
|
| Radiation Tolerance | 2 | 2020 | 639 | 0.040 |
Why?
|
| Pancreas | 1 | 2023 | 737 | 0.040 |
Why?
|
| Thioguanine | 1 | 2019 | 69 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 333 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 457 | 0.040 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 10268 | 0.040 |
Why?
|
| Lymphatic Metastasis | 6 | 2017 | 4969 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 347 | 0.040 |
Why?
|
| Analysis of Variance | 5 | 2003 | 2315 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 196 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 277 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1990 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2022 | 3561 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2019 | 313 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 697 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 497 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 669 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1436 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 14638 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 1127 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 27 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 6766 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 379 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 6233 | 0.040 |
Why?
|
| Genes, ras | 1 | 2020 | 678 | 0.040 |
Why?
|
| Age Factors | 3 | 2020 | 5441 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 1691 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 9048 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2002 | 1389 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1044 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 165 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 12039 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 15275 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 684 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 146 | 0.030 |
Why?
|
| Gastritis | 1 | 2019 | 399 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2019 | 9463 | 0.030 |
Why?
|
| Carcinoma | 2 | 1999 | 2610 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 654 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 35421 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1381 | 0.030 |
Why?
|
| Proportional Hazards Models | 6 | 2003 | 5099 | 0.030 |
Why?
|
| Nose Neoplasms | 1 | 1998 | 243 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 1111 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 529 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2360 | 0.030 |
Why?
|
| Radiation Injuries | 2 | 2000 | 1476 | 0.030 |
Why?
|
| Bilirubin | 1 | 2016 | 226 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 271 | 0.030 |
Why?
|
| Gene Components | 1 | 2014 | 15 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2856 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1553 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 4992 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 14878 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 437 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 1901 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 6193 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 104 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 3606 | 0.030 |
Why?
|
| Hong Kong | 3 | 2002 | 89 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1436 | 0.030 |
Why?
|
| Cytarabine | 1 | 2019 | 2014 | 0.030 |
Why?
|
| Incidence | 2 | 2019 | 5825 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2491 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 509 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1409 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 2033 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 109 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 2170 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 1381 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 4054 | 0.020 |
Why?
|
| Animals | 3 | 2022 | 61357 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 155 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 9053 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1998 | 1068 | 0.020 |
Why?
|
| Chromatin | 1 | 2017 | 1043 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 149 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 617 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 1002 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1195 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2192 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1458 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 1292 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 495 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 591 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3205 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1132 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1547 | 0.020 |
Why?
|
| Radiotherapy Dosage | 4 | 2000 | 4020 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6446 | 0.020 |
Why?
|
| Endosonography | 1 | 2012 | 551 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4838 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2468 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 1997 | 4317 | 0.020 |
Why?
|
| Treatment Failure | 3 | 1997 | 1430 | 0.020 |
Why?
|
| beta Catenin | 1 | 2012 | 687 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4810 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 3328 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3582 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 692 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 5405 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 1994 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 2199 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 6344 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6639 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 2 | 2000 | 227 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2017 | 2768 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2560 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3345 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 3435 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6881 | 0.010 |
Why?
|
| Child | 7 | 2003 | 30560 | 0.010 |
Why?
|
| Organizations | 1 | 2003 | 22 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2016 | 7232 | 0.010 |
Why?
|
| Asia | 1 | 2003 | 149 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 5415 | 0.010 |
Why?
|
| Quality Control | 1 | 2003 | 461 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 255 | 0.010 |
Why?
|
| Paralysis | 1 | 1999 | 54 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 3190 | 0.010 |
Why?
|
| Brachytherapy | 2 | 1997 | 1005 | 0.010 |
Why?
|
| Cranial Nerve Diseases | 1 | 1999 | 76 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 12042 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 2180 | 0.010 |
Why?
|
| Cesium | 1 | 1997 | 18 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 2051 | 0.010 |
Why?
|
| Clavicle | 1 | 1996 | 68 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 170 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 449 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 2508 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1996 | 3081 | 0.010 |
Why?
|
| Registries | 1 | 2002 | 2210 | 0.010 |
Why?
|
| Physical Examination | 1 | 1996 | 306 | 0.010 |
Why?
|
| Neck | 1 | 1996 | 394 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1998 | 1723 | 0.010 |
Why?
|
| Probability | 1 | 1994 | 886 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 1562 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1999 | 1858 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1993 | 751 | 0.010 |
Why?
|
| Remission Induction | 1 | 1998 | 3658 | 0.010 |
Why?
|
| Survival Analysis | 2 | 1993 | 9281 | 0.010 |
Why?
|
| Logistic Models | 1 | 1995 | 3429 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 4007 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2003 | 17072 | 0.000 |
Why?
|